French diabetes specialist raises €16 million in Series A

Thursday 8 July 2010

The Lyon-based company, Poxel SA, has raised €16 million in a Series A round, enabling it to advance the Phase 2 programme for its lead compound against Type 2 diabetes. The round was led by Edmond de Rothschild Investment Partners.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France